HeartFlow Inc's stock surged 6.59% during intraday trading on Thursday, showcasing a significant upward movement for the healthcare company.
The price jump comes as analysts express mixed views on the stock. While Wells Fargo and JP Morgan both cut their price targets for HeartFlow Inc, Stifel Nicolaus maintained its Buy rating with a $40 price target, highlighting a divergence in analyst sentiment.
This conflicting guidance from major financial institutions appears to have fueled investor interest, with the market reacting positively to the continued bullish stance from Stifel despite the downward revisions from other firms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.